Full history for every metric is available with a Kvantra account
Lansen Pharmaceutical Holdings Limited (0503.HK)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 89 | 57 | 54 | 54 | 54 | 66 | 65 |
| Operating profit | $m | 14 | 12 | |||||
| Net profit | $m | 16 | 0 | 18 | 88 | 1 | 9 | 7 |
| EPS reported | $ | 0.02 | 0.02 | |||||
| Operating cashflow per share | $ | 0.04 | 0.04 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | 0.04 | 0.04 | |||||
| Free cash flow | $m | 17 | 3 | |||||
| Net debt | $m | -33 | -29 | |||||
| Book value equity | $m | 122 | 124 | |||||
| Book value per share | $ | 0.29 | 0.29 | |||||
| Number of shares | m | 420.78 | 422.36 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 9.17 | - | |||||
| P/B LTM | x | 0.65 | 0.77 | |||||
| P/S LTM | x | 1.21 | 1.47 | |||||
| P/FCF LTM | x | 4.77 | 28.62 | |||||
| EV/EBITDA LTM | x | 3.04 | 4.61 | |||||
| EV/Sales LTM | x | 0.71 | 1.03 | |||||
| Earnings Yield LTM | % | 10.91% | 8.96% | |||||
| FCF Yield | % | 20.98% | 3.49% | |||||
| Quality | ||||||||
| ROE | % | 7.05% | 7.21% | |||||
| ROIC | % | 8.61% | 8.61% | |||||
| Operating margin | % | 21.60% | 21.60% | |||||
| Gross margin | % | 67.57% | 67.57% | |||||
| FCF/Sales | % | 25.30% | 25.30% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +831.82% | - | |||||
| Sales Growth YoY | % | +21.00% | - | |||||
| Net Income Growth YoY | % | +852.05% | - | |||||
| FCF Growth | % | +126.97% | - | |||||
| Operating Profit Growth | % | +61.44% | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | -100.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.89 | 0.19 | |||||
| Net Debt/EBITDA | x | -2.15 | -2.15 | |||||
| EBIT/Net interest | x | 13.45 | 13.45 | |||||
| Net debt/market cap | % | -41.40% | -30.11% | |||||
| Net debt/Equity | x | -0.27 | -0.23 | |||||
| Gross debt/equity | x | 0.15 | 0.14 | |||||
Company overview
Lansen Pharmaceutical Holdings Limited, an investment holding company, concentrates on the research, manufacturing, and global distribution of niche pharmaceutical drugs. These specialized medicines primarily address conditions in rheumatology and dermatology, serving both the People's Republic of China and international markets. The company's business operations are organized into three distinct divisions: Pharmaceuticals, Cosmetic Products, and Healthcare Products. Its product range includes generic traditional Chinese medicines, various cosmetic goods, and health-related items. Established in 2001, its main offices are situated in Ningbo, China. Lansen Pharmaceutical Holdings Limited operates as a subsidiary of Cathay International Pharma Manufacture and Distribution (China) Limited.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Lansen Pharmaceutical Holdings Limited (0503.HK)
Lansen Pharmaceutical Holdings Limited, an investment holding company, concentrates on the research, manufacturing, and global distribution of niche pharmaceutical drugs. These specialized medicines primarily address conditions in rheumatology and dermatology, serving both the People's Republic of China and international markets. The company's business operations are organized into three distinct divisions: Pharmaceuticals, Cosmetic Products, and Healthcare Products. Its product range includes generic traditional Chinese medicines, various cosmetic goods, and health-related items. Established in 2001, its main offices are situated in Ningbo, China. Lansen Pharmaceutical Holdings Limited operates as a subsidiary of Cathay International Pharma Manufacture and Distribution (China) Limited.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free